



INTERNATIONAL GENERIC AND
BIOSIMILAR MEDICINES ASSOCIATION

Info: info@igbamedicines.org

IGBA's CEO Advisory Committee Meets with WHO Director General and WHO Leadership

For immediate release
Geneva, 20 October 2022

The International Generic and Biosimilar Medicines Association's (IGBA) newly established [CEO Advisory Committee](#) held its first in-person meeting in Geneva this week and had a far-reaching exchange with the World Health Organization's (WHO) Director-General Dr. Tedros Adhanom Ghebreyesus and other WHO leaders. This was the first opportunity for Dr. Tedros to engage in a direct dialogue with the IGBA CEO Advisory Committee following its launch and the admission of IGBA as a non-State actor in official relations with WHO earlier this year.

"During the exchange with Dr. Tedros, the [incoming Chair of the IGBA CEO Advisory Committee Richard Saynor](#), outlined the essential role of generic and biosimilar medicines in global patient care and the significant contribution of the industry during the COVID-19 pandemic," commented Suzette Kox Secretary General of the IGBA Management Committee.

"The generic and biosimilar industry supplies an estimated 80% of all medicines globally, and is therefore absolutely critical to ensuring safe and affordable medicines are available to patients around the world. IGBA and the members of the CEO Advisory Committee look forward to work closely with the WHO to ensure patients have access to the quality-assured medicines they need, when they need them," said Mr. Saynor, Chief Executive Officer of Sandoz.

Ms. [Vinita Gupta](#), Chief Executive Officer of Lupin Limited, and [incoming Vice-Chair of IGBA's CEO Advisory Committee](#), added *"The leaders of the generic and biosimilar industry have come together to address key policy issues that impede access to affordable medicines and we are pleased to directly partner with WHO within the spirit of the UN Sustainable Development Goals"*.

About us: The International Generic and Biosimilar medicines Association (IGBA) strengthens cooperation between associations representing manufacturers of generic and biosimilar medicines from around the world. Adopting a patient centric approach, IGBA works to improve patients' access to quality-assured, safe and cost-effective medicines by promoting competition and enabling innovation in the pharmaceutical sector and sustainable economic contributions for all stakeholders. For more details, regarding IGBA and its member associations, see the IGBA website at: www.igbamedicines.org.



IGBA's CEO Advisory Committee was established in February 2022 as a forum for generic and biosimilar medicines industry leaders to discuss broad strategic issues, and to engage and position the industry on a range of critical policy matters.

For more information:

- [IGBA establishes a CEO Advisory Committee](#)
- [IGBA's Newly Launched CEO Advisory Committee Holds Inaugural Meeting with WTO Director General](#)